| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/28/2005 | US20050163849 Compositions and dosage forms for enhanced absorption of iron |
| 07/28/2005 | US20050163848 complexed with transport moiety comprising a lauryl sulfate salt; complex provides an enhanced absorption of the drug in the lower gastrointestinal tract; to control seizures or neuropathic pain with once daily administration |
| 07/28/2005 | US20050163847 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
| 07/28/2005 | US20050163846 Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
| 07/28/2005 | US20050163845 tablet comprising a nucleus coated with polymeric film, insoluble and impermeable to water including laser cut incisions delimiting an area having exactly programmable and defined dimensions and geometric shape; in biological fluids, the portion of film inside incision(s) detaches and releases drug |
| 07/28/2005 | US20050163844 Controlled and sustained delivery of nucleic acid-based therapeutic agents |
| 07/28/2005 | US20050163843 release-retarding material does not comprise hydroxpropyl methylcellulose; Controlled-release formulations, such as longer acting formulations that can be administered once daily or even less frequently |
| 07/28/2005 | US20050163842 Rosiglitazone and metformin formulations |
| 07/28/2005 | US20050163841 to controllably deliver orally a drug at a substantially zero order delivery rate a during a window; improved oral absorption |
| 07/28/2005 | US20050163840 Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
| 07/28/2005 | US20050163839 Oral controlled release pharmaceutical composition containing metaxalone as active agent |
| 07/28/2005 | US20050163838 Effervescent oral opiate dosage forms and methods of administering opiates |
| 07/28/2005 | US20050163837 Rosiglitazone formulations |
| 07/28/2005 | US20050163836 breaking strength of above 90 N.; having a disintegration time of 5-9 minutes; microcrystalline cellulose of small particle size is wholly or partially suspended in the granulating liquid and this suspension is used for the granulation |
| 07/28/2005 | US20050163835 Gefitinib or salt with and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether; increased absorption and/or bioavailability and may reduce inter-patient variability; prevents precipitation in higher pH upper GI |
| 07/28/2005 | US20050163834 Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
| 07/28/2005 | US20050163833 gelatin-free soft capsules containing active ingredients; reduced glyceamic index; Significant improvements, especially with regard to brittleness, storage stability in changing conditions and sorption behavior |
| 07/28/2005 | US20050163832 liposome, safe and efficient delivery of agents, i.e. proteins, nucleic acids, small molecules and/or other drugs, into cell of higher organism in vitro or in vivo; transducing polypeptide-lipid vesicle complex; protein transduction domain of HIV-1 TAT protein, VP22 herpes virus or Antennapedia protein |
| 07/28/2005 | US20050163831 Patch for transdermal administration |
| 07/28/2005 | US20050163830 matrix-forming polymer comprises at least one active substance and at least one gas-forming component; comprises at least one carbon dioxide-forming substance reducing or suppressing the unpleasant taste of the active substance |
| 07/28/2005 | US20050163829 Device and patch for controlled release of vanillin |
| 07/28/2005 | US20050163828 increased hardness, reduced tackiness and improved handling characteristics; having a weight no greater than 1 gram |
| 07/28/2005 | US20050163827 Transdermal therapeutic delivery system |
| 07/28/2005 | US20050163824 Modified polymeric films |
| 07/28/2005 | US20050163812 applying a physiologically compatible composition containing hydrated synthetic cells in a lipid matrix in an amount effective to treat skin |
| 07/28/2005 | US20050163808 Group A streptococcal polysaccharide immunogenic compositions and methods |
| 07/28/2005 | US20050163803 Non-animal origin stabilizers and processes for producing the same |
| 07/28/2005 | US20050163788 Prevention and treatment of amyloidogenic disease |
| 07/28/2005 | US20050163752 Human interferon-beta formulations |
| 07/28/2005 | US20050163750 Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby |
| 07/28/2005 | US20050163745 Immunogens; polyesters; glycolic acid-lactic acid copolymers; vaccines; delayed release; mucosal/parenteral administration |
| 07/28/2005 | US20050163728 A mixture of polypeptides, as calcium binding protein for reducing bone loss and reducing renal phosphate excretion; biodrug for treating bone disorders; injectable solution or dispersed in toothpaste or a mouthwash or gum patch |
| 07/28/2005 | US20050163727 Topical, oral administration; mouthrinses; microbiocides; bactericides; prevents spread of pathogenic oral bacteria, toxins and endotoxins, and resultant inflammatory cytokines and mediators; cardiovascular disease, stroke, atherosclerosis |
| 07/28/2005 | US20050163726 Respiratory disorders; antiinflamatory agents; capsules containing inhalable powder; aerosols |
| 07/28/2005 | US20050163725 Method for administration of growth hormone via pulmonary delivery |
| 07/28/2005 | US20050163724 Contains steroidal anti-inflammatory drug, carrier (saccharides, sugar alcohols, amino acids), and water |
| 07/28/2005 | US20050163723 Synthesis of small particles |
| 07/28/2005 | US20050163722 Optimised formulation of tobramycin for aerosolization |
| 07/28/2005 | US20050163721 Container for the generation of therapeutic microfoam |
| 07/28/2005 | US20050163720 May be used to prepare novel aerosol formulations, and can be advantageous in terms of improving the stability of the aerosol formulation, reducing drug deposition, increasing shelf life |
| 07/28/2005 | US20050163719 Buccal, polar and non-polar spray containing diazepam |
| 07/28/2005 | US20050163717 Abuse potential reduction in abusable substance dosage form |
| 07/28/2005 | US20050163716 Methods of preparing gaseous precursor-filled microspheres |
| 07/28/2005 | US20050163714 Capsules of multilayered neutral polymer films associated by hydrogen bonding |
| 07/28/2005 | US20050161857 Polymeric fibre and method for making same |
| 07/28/2005 | US20050160538 Fragance of 3-cis hexenol and ethanolamine to improve odor |
| 07/28/2005 | DE202005005094U1 Composition, useful for the treatment of diseases or conditions of eye, comprises extract and/or tincture obtained from plant and/or plant parts of Euphrasia officinalis, and sodium chloride |
| 07/28/2005 | DE202005001888U1 Antitumor composition comprises interleukin-2 and sodium dodecyl sulfate in the form of microaggregates |
| 07/28/2005 | DE10361599A1 Flüssigformulierung von Antikörperkonjugaten Liquid formulation of antibody conjugates |
| 07/28/2005 | DE10361598A1 The freeze-dried pharmaceutical composition as the conjugate of an antibody with a mytansinoid, for the treatment of cancers, is set to a given concentration and pH value before freeze drying |
| 07/28/2005 | DE10360847A1 Medical lubricant gel, useful in ear, nose and throat medicine, urology and gynecology, comprising gel former, care component and antimicrobial |
| 07/28/2005 | DE10360592A1 Pflastersystem zur Verabreichung von Antihistaminika Paving system for administration of antihistamines |
| 07/28/2005 | DE10043321B4 Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and Lactationshemmung |
| 07/28/2005 | CA2559352A1 Lipid compositions and use thereof |
| 07/28/2005 | CA2553781A1 Compositions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug |
| 07/28/2005 | CA2552887A1 Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid |
| 07/28/2005 | CA2552677A1 Controlled release cgrp delivery composition for cardiovascular and renal indications |
| 07/28/2005 | CA2552524A1 Lipid compositions and methods of use |
| 07/28/2005 | CA2552521A1 Compositions comprosing memantine and polyanionic polymers for administration to the eye |
| 07/28/2005 | CA2552484A1 Confection product containing urea |
| 07/28/2005 | CA2552004A1 Methods for tailoring the immune response to an antigen or immunogen |
| 07/28/2005 | CA2551121A1 Crosslinked hyaluronic acid compositions for tissue augmentation |
| 07/28/2005 | CA2549524A1 Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| 07/27/2005 | EP1557463A1 Improved methods for processing activated protein C |
| 07/27/2005 | EP1557197A1 Dihydroalkoxybenzyloxopyrimidine (DABO) derivatives exhibiting spermicidal activity |
| 07/27/2005 | EP1557179A1 Analgesic dosage forms that are unable to be inhaled or injected |
| 07/27/2005 | EP1557177A1 Antigen for transcutaneous immunisation |
| 07/27/2005 | EP1557170A2 Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections |
| 07/27/2005 | EP1557167A1 Viral inhibition by long-chain alcohols alkanes fatty acids and amides |
| 07/27/2005 | EP1557164A1 Adhesive patch containing tulobuterol |
| 07/27/2005 | EP1557162A1 Transdermal patch for administering antihistamines |
| 07/27/2005 | EP1557151A1 Solid dosage form |
| 07/27/2005 | EP1557146A1 Heat generating article |
| 07/27/2005 | EP1556428A2 Fast curing compositions |
| 07/27/2005 | EP1556413A1 Methods and compositions for the treatment of ischemic reperfusion |
| 07/27/2005 | EP1556158A1 Method for the production of powdered active substance formulations by means of compressible fluids |
| 07/27/2005 | EP1556135A2 Transdermal delivery system for anti-emetic medication |
| 07/27/2005 | EP1556134A2 Transdermal delivery system for dried particulate or lyophilized medications |
| 07/27/2005 | EP1556133A2 Transdermal delivery system for water insoluble drugs |
| 07/27/2005 | EP1556091A1 Gamma irradiation of solid nanoparticulate active agents |
| 07/27/2005 | EP1556090A1 Polymer compositions for administration to animals |
| 07/27/2005 | EP1556066A2 Compositions and methods of use for a fibroblast growth factor |
| 07/27/2005 | EP1556061A2 Photokinetic delivery of biologically active substances using pulsed incoherent light |
| 07/27/2005 | EP1556050A1 Pharmaceutical compositions of ganciclovir |
| 07/27/2005 | EP1556048A1 Effervescent formulations comprising apomorphine |
| 07/27/2005 | EP1556026A1 Novel pharmaceutical formulations of modafinil |
| 07/27/2005 | EP1556024A1 Pulsatile release compositions of milnacipran |
| 07/27/2005 | EP1556023A1 Nutritional or therapeutic compositions |
| 07/27/2005 | EP1556022A1 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 07/27/2005 | EP1556018A1 Sustained release porous microparticles for inhalation |
| 07/27/2005 | EP1556017A1 Dosage form providing ascending release of liquid formulation |
| 07/27/2005 | EP1556016A1 Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers |
| 07/27/2005 | EP1556015A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 07/27/2005 | EP1556014A1 Sustained release compositions containing alfuzosin |
| 07/27/2005 | EP1556013A1 Deferacirox dispersible tablets |
| 07/27/2005 | EP1556012A2 Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier |
| 07/27/2005 | EP1556011A1 Therapeutic compositions |
| 07/27/2005 | EP1556010A2 Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
| 07/27/2005 | EP1556009A2 Cosmetic and pharmaceutical foam |
| 07/27/2005 | EP1556007A2 Substituted tetracycline compounds for the treatment of malaria |